Literature DB >> 9759620

The effects of standard and low molecular weight heparin on bone nodule formation in vitro.

M Bhandari1, J Hirsh, J I Weitz, E Young, T J Venner, S G Shaughnessy.   

Abstract

Previously, we demonstrated in a rat model of heparin-induced osteoporosis that low molecular weight heparin (LMWH) produces less bone loss than unfractionated heparin, and that only heparin increases osteoclast number and activity. In contrast, both heparin and LMWH were found to decrease osteoblast function to a similar extent, possibly because at the doses tested both agents produced maximal inhibition. To examine the relative effects of heparin and LMWH on osteoblast function more closely we used an in vitro bone nodule assay, together with measurements of alkaline phosphatase (ALP) activity. Both agents inhibited bone nodule formation and ALP activity in a concentration-dependent manner, but 6 to 8-fold higher concentrations of LMWH were required to achieve equivalent effects. The effect of heparin on osteoblast function was both chain-length and negative charge-dependent because the ability of defined heparin fragments to inhibit nodule formation correlated with their molecular weight (r = 0.98), and N-desulfated heparin was less inhibitory than heparin. In contrast, the effect of heparin on osteoblast function was pentasaccharide-independent because heparin with low affinity for antithrombin had similar activity to heparin with high antithrombin activity. These findings help to explain mounting clinical evidence that the risk of osteoporosis is lower with LMWH than with heparin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759620

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  How to handle low-molecular-weight heparins in patients with decreased renal function: an open issue.

Authors:  Giuseppe Stefano Netti; Maurizio Margaglione; Loreto Gesualdo
Journal:  Intern Emerg Med       Date:  2008-09-20       Impact factor: 3.397

Review 3.  Update on heparin: what do we need to know?

Authors:  Daniel S Weitz; Jeffrey I Weitz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

Review 4.  Anticoagulation therapy in children.

Authors:  Milind D Ronghe; Christina Halsey; Nicholas J Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Cancer and thrombosis: mechanisms and treatment.

Authors:  Steven R Deitcher
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

Review 6.  Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Authors:  Jawed Fareed; Debra Hoppensteadt; Jeanine Walenga; Omer Iqbal; Qing Ma; Walter Jeske; Taqdees Sheikh
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts.

Authors:  Tobias Winkler; Carsten Perka; Dörte Matziolis; Georg Matziolis
Journal:  Open Orthop J       Date:  2011-03-16

8.  The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.

Authors:  Gandhi N Solayar; Pauline M Walsh; Kevin J Mulhall
Journal:  BMC Musculoskelet Disord       Date:  2011-10-28       Impact factor: 2.362

9.  Deep vein thrombosis: a clinical review.

Authors:  Emeka Kesieme; Chinenye Kesieme; Nze Jebbin; Eshiobo Irekpita; Andrew Dongo
Journal:  J Blood Med       Date:  2011-04-29

10.  Glycosaminoglycan and growth factor mediated murine calvarial cell proliferation.

Authors:  Kerry J Manton; Larisa M Haupt; Kumeri Vengadasalam; Victor Nurcombe; Simon M Cool
Journal:  J Mol Histol       Date:  2007-07-25       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.